Biomarkers Market (Diagnostic Applications in Risk Assessment, Molecular Diagnostics, Disease Diagnosis, Drug Discovery & Development, Drug Formulation, Forensic Applications and Others) – Global Industry Analysis, Emerging Technologies, Competitive Intelligence, Growth Trends, Size, Share, Opportunities and Forecast, 2013 – 2020

“Biomarker technology is evidencing increased application from key segments such as disease diagnosis, drug development and formulation, diagnosis for exposure of certain harmful chemical and prognostic treatments. Biomarkers are novel diagnostic solutions and advancement in it its development and understanding of human genome promotes its application in diagnosis of disease on molecular basis. Pharmaceutical companies which are interested in introducing novel diagnostic solution are increasing partnership and collaboration with private laboratories, educational institute and these companies are also increasing their investments in research and development.

The global market for diagnostic biomarker expected to reach about $30.6 billion in 2020 growing at CAGR of 16% from 2013 to 2020. Disease diagnostic application remains the key area of application that is expected to reach 6.1 $billion in 2020. However application of diagnostic biomarkers in forensics and molecular diagnostics is catching up quite significantly. Molecular diagnostics is expected to grow at a CAGR of 17.6% from 2013 to 2020.

Scope

Global diagnostic Biomarker report segments the market in three categories; market by technologies, market by services, and market by diseases. These markets are expected to show elevated growth in future as biomarkers are providing diagnostic service for complex disease. As it is non-invasive procedure it motivates the use of biomarkers than conventional diagnostic applications. This report focuses on key factors impacting the diagnostic biomarker market used in risk assessment, molecular diagnostics, disease diagnosis, drug discovery and development, drug formulation, forensic applications and others. Diagnostic biomarker and its applications in emerging segments of omics, imaging technologies, personalized medicine, and bioinformatics are all discussed in detail.

Key deliverables

Biomarkers of disease are majorly covered by oncology, cardiovascular and Neurology disease. Oncology biomarkers are covering more market share as compared to other disease biomarkers. Other biomarker are facing some ethical and technical problem such complex sample preparation process.

Biomarkers in service has open a new market for sample preparation for disease diagnosis which enables clinicians to save time required for preparing sample to conduct diagnostic test. Biomarkers are also resolving drug validation problem by analyzing viability of drug discovered by pharmaceutical research.

The geographic analysis is based on North America., Europe, Asia-Pacific and Rest of the World.

The key players in this market that are also profiled in the report include Roche Diagnostic Limited (Switzerland), Siemens Healthcare (Germany), Abbott Laboratories Inc. (U.S.), Thermo Fisher Scientific, Inc. (U.S.), Agilent Technologies Inc. (U.S.), Bio-Rad Laboratories Inc. (U.S.), Aushon BioSystem Inc. (M.A.), Epistem Ltd.(U.K.), G.E. Healthcare Inc.(U.K).

Key benefits of report

Assessment and ranking the factors that favour the market growth and those factors which act as a hindrance for the growth of the market
The market sizing and estimation period is from 2013 to 2020. Two historic years include 2011 and 2012
The report identifies and analyses top investment pockets and top winning strategies for diagnostic biomarker market
The report analyses the various strategies adopted by some of the key companies in the market
The report tracks and analyses key innovations and patents for biomarkers in the last five years”

“1.    Introduction
1.1      Scope and Coverage

1.2      Report Description

  2    Executive Summary

2.1      Biomarker Diagnosis Vs. Conventional Diagnosis

2.2      Why Diagnostic Biomarkers are Used in Diagnosis and Drug Development?

  3    Market Overview

3.1      Key Application of Diagnostic Biomarkers in Top Technologies

3.1.1   Omics Technology

3.1.1.1    Applications of Omics Technology

3.1.1.1.1  Lung Disease Identification

3.1.1.1.2  Quantifying Abnormalities

3.1.1.1.3  Genetic Trait Diagnosis

3.1.1.1.4  Analyzing Drug Efficiency

3.1.1.1.5  Functional Food Development

3.1.1.1.6  Pharmacogenomics

3.1.1.1.7  Drivers

3.1.1.1.8  Restraints

3.1.1.1.8.1 Lengthy Process

3.1.1.1.8.2 Ethical Problems

3.1.1.1.8.3 Sample Collection

3.1.1.1.8.4 Gene Expression

3.1.1.1.8.5 Inefficiency in Pre-Disease Identification

3.1.2   Imaging Technology

3.1.2.1    Application of Diagnostic Imaging Technology

3.1.2.2    Drivers

3.1.2.2.1  Faster Test Result

3.1.2.2.2  Improved Nursing Services

3.1.2.2.3  Noninvasive Technique

3.1.2.3    Restraints

3.1.2.3.1  Radiation Effect

3.1.2.3.2  Complex Process

3.1.2.3.3  Genetic Variation

3.1.2.4    Trends

3.1.3   Bioinformatics

3.1.3.1    Applications of Bioinformatics

3.1.3.2    Drivers

3.1.3.2.1  Open Source of Information

3.1.3.2.2  Relevant Information

3.1.3.2.3  Forecasting of Information

3.1.3.3    Restraints

3.1.3.3.1  Difficulty in Practical Application

3.1.3.3.2  Over-Fitting

3.1.3.3.3  Complex Operation Process

3.1.3.3.4  Security Issue

3.1.3.3.5  Costly Management

3.1.3.3.6  Virtual Storage

3.1.4   Personalized Medicines

3.1.4.1    Drivers

3.1.4.1.1  Unique Solution

3.1.4.1.2  Minimal Invasive

3.1.4.1.3  Reduction in Failure

3.1.4.1.4  Effective Prescription

3.1.4.2    Restraints

3.1.4.2.1  Need Specialized Setup for Treatment

3.1.4.2.2  Liability Issue

3.1.4.2.3  Ethical Question

3.1.5   Others (Nutritional Technology)

3.2      Importance of Non-Invasive Diagnostics

3.3      Key Advantages of Dm

3.4      Regulatory Scenario

3.5      Reimbursement Issues

3.6      Key Patents and Analysis

3.7      Top Ten Factors Impacting DBM Market

3.7.1   Non-Invasive Technique

3.7.2   Drug Discovery and Development

3.7.3   Cost Effective Tool for Diagnosis

3.7.4   Multi-Marker Application

3.7.5   Accuracy and Reliability

3.7.6   Ethical Issues

3.7.7   Gene Level Diagnosis

3.7.8   Complex Processes

3.7.9   Government Regulations

3.7.10 Reimbursement Issues

3.8      Top Investment Pockets

3.9      Market Intelligence

3.9.1   Top Three Winning Strategies

3.9.1.1    Product Launch

3.9.1.2    Collaboration and Agreement

3.9.1.3    Merger and Acquisition

3.10    Market Dynamics

3.10.1 Drivers

3.10.1.1 Cost Effective

3.10.1.2 Non-Invasive

3.10.1.3 Accuracy in Result

3.10.1.4 Assistant in Clinical Trials

3.10.1.5 Multi-Marker Application

3.10.1.6 Gene Level Diagnosis

3.10.2 Restrains

3.10.2.1 Government Regulation

3.10.2.2 Ethical Problems

3.10.2.3 Conformation in Result

3.10.2.4 Complex Process

3.10.3 Opportunity

3.10.3.1 Local Market

3.10.3.2 Personalized Medicine

3.10.3.3 Tissue Specific Treatment

  4    Global Diagnostic Biomarker Market by Types

4.1      Biomarker of Exposure

4.2      Biomarkers of Disease

  5    Global Diagnostic Biomarker Market by Applications

5.1      Risk Assessment

5.1.1   Applications

5.1.1.1    Oncology Treatment

5.1.1.2    Cardiovascular Treatment

5.1.2   Drivers

5.1.2.1    Forecasting of Abnormal Conditions

5.1.2.2    Cost Effective

5.1.3   Restraints

5.1.3.1    Government Regulations

5.1.3.2    Ethical Issues

5.2      Development of Molecular Diagnostic

5.2.1   Application

5.2.1.1    Prenatal Diagnostics

5.2.1.2    Human Clinical Molecular Diagnostic Testing

5.2.1.3    Veterinary Molecular Diagnostic Testing

5.2.1.4    Identity Testing

5.2.1.5    Histocompatibility Testing

5.2.2   Drivers

5.2.2.1    Uniformity in Test Result

5.2.2.2    Cost Effective

5.2.2.3    Fast Result

5.2.2.4    More Profitable

5.2.2.5    Automation

5.2.3   Restraints

5.2.3.1    Not Applicable for Twins Genomes

5.2.3.2    Government Regulations

5.2.3.3    Ethical Issues

5.3      Disease Diagnosis

5.3.1   Oncology

5.3.1.1    Drivers

5.3.1.2    Restraints

5.3.1.2.1  Complex Process

5.3.1.2.2  Conformation in Result

5.3.1.2.3  Used for Early Diagnosis Only

5.3.2   Cardiology

5.3.2.1    Application

5.3.2.2    Drivers

5.3.2.2.1  Cost Effective

5.3.2.2.2  Tissue Specific

5.3.2.2.3  Accurate Result

5.3.2.3    Restraints

5.3.2.3.1  Loss of Specificity

5.3.2.3.2  Low Specificity

5.3.2.3.3  Low Sensitivity

5.3.3   Neurology

5.3.3.1    Application

5.3.3.2    Drivers

5.3.3.2.1  Relevant Information

5.3.3.2.2  Efficient Diagnosis

5.3.3.2.3  Assistant in Clinical Trials

5.3.3.3    Restraints

5.3.3.3.1  Complex Process

5.3.3.3.2  Chromosomal Variation

5.3.3.3.3  Hurdles in Tracking

5.3.3.4    Alzheimer’s

5.3.3.5    Multiple Sclerosis

5.3.3.6    Parkinson’s Disease

5.3.3.7    Others (Renal Diseases, Urinal Disease)

5.4      Drug Discovery and Development

5.4.1   Application

5.4.2   Drivers

5.4.2.1    Increased Efficiency

5.4.2.2    High Quality Support

5.4.2.3    Cost Effective

5.4.2.4    Collaboration for Novel Development

5.4.3   Restraints

5.4.3.1    Drug Metabolism

5.4.3.2    Stability of Biomarkers

5.4.3.3    Complex Process

5.5      Drug Formulation

5.5.1   Application

5.5.2   Drivers

5.5.3   Restraint

5.6      Forensic Application

5.7      Others (Dna Fingerprinting and Others)

5.7.1   Blood Alcohol Concentration Biomarker

5.7.2   Dna Fingerprinting

  6    Global Diagnostic Biomarker Market by Services

6.1      Sample Preparation

6.1.1   Application

6.1.1.1    Biological Mass Spectrometry

6.1.2   Drivers

6.1.2.1    Cost Effective

6.1.2.2    Sample Rigidity

6.1.2.3    Efficient Forensic Studies

6.1.3   Restraints

6.1.3.1    Complex Structure

6.1.3.2    Lack of Effectiveness

6.1.3.3    Extensive Fractionation

6.1.3.4    Loss of Biological Compounds

6.2      Assay Development

6.2.1   Application

6.2.1.1    Clinical Trials

6.2.1.2    Drug Development and Validation

6.2.1.3    Others

6.2.2   Drivers

6.2.2.1    Accuracy

6.2.2.2    Cost Effective

6.2.2.3    Timely Result

6.2.3   Restraints

6.2.3.1    Complexity in Technique

6.2.3.2    Tissue Specific

6.3      Biomarker Validation and Testing

6.3.1   Drivers

6.3.1.1    Reduce Failure Rate

6.3.2   Restraints

6.3.2.1    Clinical Errors

6.3.2.2    Time Consuming

6.4      Other Services

  7    Global Diagnostic Biomarker Market by Geography

7.1      North America

7.2      Europe

7.3      Asia-Pacific

7.4      Row (Rest of World)

  8    Competitive Landscape

8.1      Product Launch

8.1.1   Recent Development

8.2      Collaboration and Partnership

8.2.1   Recent Development

8.3      Clearance and Approval

8.3.1   Recent Development

8.4      Mergers and Acquisition

8.4.1   Recent Development

  9    Company Profile

9.1      Abbott Laboratories, Inc.

9.1.1   Company Overview

9.1.2   Company Snapshot

9.1.3   Business Performance

9.1.4   Strategic Moves and Developments

9.1.4.1    Principal Strategies

9.1.4.2    Secondary Strategies

9.1.5   Swot Analysis & Strategic Conclusions

9.2      Agilent Technologies Inc.

9.2.1   Company Overview

9.2.2   Company Snapshot

9.2.3   Business Performance

9.2.4   Strategic Moves and Developments

9.2.4.1    Primary Strategies

9.2.4.2    Secondary Strategies

9.2.5   Swot Analysis & Strategic Conclusions

9.3      Aushon Biosystem

9.3.1   Company Profile

9.3.2   Company Snapshot

9.3.3   Strategic Moves and Developments

9.3.3.1    Primary Strategies

9.3.3.2    Secondary Strategies

9.3.4   Swot Analysis & Strategic Conclusions

9.4      Bio-Rad Laboratories

9.4.1   Company Profile

9.4.2   Company Snapshot

9.4.3   Business Performance

9.4.4   Strategic Moves and Developments

9.4.4.1    Primary Strategies

9.4.4.2    Secondary Strategies

9.4.5   Swot Analysis & Strategic Conclusions

9.5      Eisai Co. Ltd.

9.5.1   Company Profile

9.5.2   Company Snapshot

9.5.3   Business Performance

9.5.4   Strategic Moves and Developments

9.5.4.1    Primary Strategies

9.5.4.2    Secondary Strategies

9.5.5   Swot Analysis & Strategic Conclusions

9.6      Epistem Ltd.

9.6.1   Company Profile

9.6.2   Company Snapshot

9.6.3   Business Performance

9.6.4   Strategic Moves and Developments

9.6.4.1    Primary Strategies

9.6.4.2    Secondary Strategies

9.6.5   Swot Analysis & Strategic Conclusions

9.7      Ge Healthcare

9.7.1   Company Profile

9.7.2   Company Snapshot

9.7.3   Business Performance

9.7.4   Strategic Moves and Developments

9.7.4.1    Principle Strategies

9.7.4.2    Secondary Strategies

9.7.5   Swot Analysis & Strategic Conclusions

9.8      Roche Diagnostics Limited

9.8.1   Company Profile

9.8.2   Company Snapshot

9.8.3   Business Performance

9.8.4   Strategic Moves and Developments

9.8.4.1    Principal Strategies

9.8.4.2    Secondary Strategies

9.8.5   Swot Analysis & Strategic Conclusions

9.9      Siemens AG

9.9.1   Company Profile

9.9.2   Company Snapshot

9.9.3   Business Performance

9.9.4   Strategic Moves and Developments

9.9.4.1    Primary Strategies

9.9.4.2    Secondary Strategies

9.9.5   Swot Analysis & Strategic Conclusions

9.10    Thermo Fisher Scientific Inc.

9.10.1 Company Profile

9.10.2 Company Snapshot

9.10.3 Business Performance

9.10.4 Strategic Moves and Developments

9.10.4.1 Primary Strategies

9.10.4.2 Secondary Strategies

9.10.5 Swot Analysis & Strategic Conclusions”

“Table 1   Global Diagnostic Biomarker Market by Revenue 2011-2020 ($Million)

Table 2   Global Diagnostic Biomarker Market by Application 2011-2020 ($Million)

Table 3   Global Diagnostic Biomarker Market for Technology 2011-2020 ($Million)

Table 4   Diagnostic Biomarker Application Market 2011-2020 ($Million)

Table 5   Diagnostic Biomarker Application Market 2011-2020 ($Million)

Table 6   Global Diagnostic Biomarker Market of Imaging Technology 2011-2020 ($Million)

Table 7   Global Diagnostic Biomarker Market of Bioinformatics 2011-2020 ($Million)

Table 8   Global Diagnostic Biomarker Market of Personalized Medicine 2011-2020 ($Million)

Table 9   Global Diagnostic Biomarker Market of Other Diseases 2011-2020 ($Million)

Table 10 Biomarkers Market by Types in 2011-2020 ($Million)

Table 11 Global Market for Biomarkers of Exposure in 2011-2020 ($Million)

Table 12 Global Market for Biomarkers of Exposure in 2011-2020 ($Million)

Table 13 Diagnostic Biomarker Application Market in 2011-2020 ($Million)

Table 14 Global Diagnostic Biomarker Market Application Market in 2011-2020 ($Million)

Table 15 Global Diagnostic Biomarker Market of Risk Assessment in 2011-2020 ($Million)

Table 16 Global Diagnostic Biomarker Market for Development of Molecular Diagnostic in 2011-2020 ($Million)

Table 17 Diagnostic Biomarker Market of Disease Diagnosis in 2011-2020 ($Million)

Table 18 Global Diagnostic Biomarker Market for Development of Molecular Diagnostic in 2011-2020 ($Million)

Table 19 Global Diagnostic Biomarker Market of Cardiology Diagnosis in 2011-2020 ($Million)

Table 20 Global Diagnostic Biomarker Market of Cardiology Diagnosis in 2011-2020 ($Million)

Table 21 Global Diagnostic Biomarker Market of Neurology Diagnosis in 2011-2020 ($Million)

Table 22 Diagnostic Biomarker Market for Neurology Disease Diagnosis in 2011-2020 ($Million)

Table 23 Global Diagnostic Biomarker Market of Other Disease Diagnosis in 2011-2020 ($Million)

Table 24 Global Diagnostic Biomarker Market of Other Disease Diagnosis in 2011-2020 ($Million)

Table 25 Global Diagnostic Biomarker Market of Drug Formulation in 2011-2020 ($Million)

Table 26 Global Diagnostic Biomarker Market of Forensic Application in 2011-2020 ($Million)

Table 27 Global Diagnostic Biomarker Market of Other Diseases in 2011-202 ($Million)

Table 28 Diagnostic Biomarker Market of Services in 2011-202($Million)

Table 29 Global Diagnostic Biomarker Market of Services in 2011-2020 ($Million)

Table 30 Global Diagnostic Biomarker Market of Sample Preparation in 2011-2020 ($Million)

Table 31 Global Diagnostic Biomarker Market of Assay Development in 2011-2020 ($Million)

Table 32 Global Diagnostic Biomarker Market of Biomarker Validation in 2011-2020 ($Million)

Table 33 Global Diagnostic Biomarker Market of Other Services in 2011-2020 ($Million)

Table 34 Global Diagnostic Biomarker Market in 2011-2020 ($Million)

Table 35 Types of Developments From 2013-2010

Table 36 Recent Development in Product Launch

Table 37 Product Launches From 2013-2010

Table 38 Collaboration and Partnership

Table 39 Partnership and Collaboration From 2013-2010

Table 40 Recent Development in Clearance and Approval

Table 41 Diagnostic Biomarker Approval and Clearance From 2013-2010

Table 42 Recent Development in Mergers and Acquisition

Table 43 Merger and Acquisition From 2013-2010

Table 44 Abbott Laboratories Business Snapshot

Table 45 Agilent Technologies Inc. Business Snapshot

Table 46 Aushon Biosystem Business Snapshot

Table 47 Bio-Rad Laboratories Business Snapshot

Table 48 Eisai Co. Ltd Business Snapshot

Table 49 Epistem Company Business Snapshot

Table 50 GE Healthcare Business Snapshot

Table 51 Roche Diagnostics Limited Business Snapshot

Table 52 Siemens Inc. Business Snapshot

Table 53 Thermo Fisher Scientific Inc. Business Snapshot”

“Figure 1  Patents Application Filled by General Electrical for Imaging Technology in India (2012)

Figure 2      Spider-Chart for Changes in Key Advantages From 2013-2020

Figure 3      Expected Growth of Biomarkers Application for Cancer Testing

Figure 4      Patent Analysis by Geography 2013

Figure 5      Top 10 Key Strategies Spider Chart 2012-2020

Figure 6      Expected Growth in CAGR From 2011-2020 for Diagnostic Biomarker Technology

Figure 7      Expected Growth in CAGR From 2011-2020 for Diagnostic Biomarkers in Application

Figure 8      Expected Growth in CAGR From 2011-2020 for Diagnostic Biomarkers in Services

Figure 9      Top 3 Wining Strategies From 2012-2020

Figure 10    Top 10 Countries in Cancer Population (Per 100,000 People) 2011

Figure 11    Cancer Statistics for Estimated New Cases and Deaths in U.S. for 2012

Figure 12    Leading Causes of Mortality in U.S. 2012

Figure 13    Cost on Alzheimer`S Disease to U.S. in 2013 (in Billion)

Figure 14    Estimated Deaths Vs. Estimated Cases in Different Types of Cancer in North America 2013

Figure 15    Developmental Strategies Adopted From 2013-2010

Figure 16    Diagnostic Biomarker Product Launch by Companies From 2013-2010

Figure 17    Partnership and Collaboration of Companies From 2013-2010

Figure 18    Clearance and Approval of Top 5 Companies From 2013-2010

Figure 19    Mergers and Acquisition From 2013-2010

Figure 20    Abbott Laboratories, Inc. Financial Revenues by Business Units (2012)

Figure 21    Abbott Laboratories, Inc.  Financial Revenues by Geography (2012)

Figure 22    SWOT Analysis of Abbott Laboratories

Figure 23    Agilent Technologies Inc. Financial Revenues by Business Units (2012)

Figure 24    Agilent Technologies Inc. Financial Revenues by Geography (2012)

Figure 25    SWOT Analysis of Agilent Technologies

Figure 26    SWOT Analysis of Aushon Biosystem

Figure 27    Bio-Rad Laboratories Financial Revenues by Business Units (2012)

Figure 28    Bio-Rad Laboratories Financial Revenues by Geography (2012)

Figure 29    SWOT Analysis of Bio-Rad Laboratories

Figure 30    Eisai Co. Ltd Financial Revenues by Business Units (2012)

Figure 31    Eisai Co. Ltd Financial Revenues by Geography (2012)

Figure 32    SWOT Analysis of Eisai Co. Ltd

Figure 33    Epistem Financial Revenues by Business Units (2012)

Figure 34    Epistem Financial Revenues by Geography (2012)

Figure 35    SWOT Analysis of Epistem

Figure 36    GE Healthcare Financial Revenues by Business Units (2012)

Figure 37    GE Healthcare Financial Revenues by Geography (2012)

Figure 38    SWOT Analysis GE Healthcare

Figure 39    Roche Diagnostics Limited Financial Revenues by Business Units (2012)

Figure 40    Roche Diagnostics Limited Financial Revenues (Diagnostic Division) by Geography (2012)

Figure 41    SWOT Analysis of Roche Diagnostics Limited

Figure 42    Siemens Inc. Financial Revenues by Business Units (2012)

Figure 43    Siemens Inc. Financial Revenues by Geography (2012)

Figure 44    SWOT Analysis of Siemens

Figure 45    Thermo Fisher Scientific Inc. Financial Revenues by Business Units (2012)

Figure 46    Thermo Fisher Scientific Inc. Financial Revenues by Geographic Areas (2012)

Figure 47    SWOT Analysis of Thermo Fisher Scientific Inc”